Latest News

Oslo, Norway, 8 November 2018: Photocure ASA (OSE:PHO), today reported a revenue growth of 42% in local currency for the U.S. market in the third quarter of 2018, contributing to total Hexvix/Cysview revenues of NOK 43.5 million (Q3 2017: NOK 35.5 million) and a recurring EBITDA of NOK -3.1 million (NOK -9.6 million).

Photocure will present its third quarter report on Thursday 8 November 2018 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

New data on Urine Cytology in the management of bladder cancer patients is now published in the prestigious peer reviewed BJUI journal (British Journal of Urology International). The analysis shows that relying on Cytology alone, especially for high risk patients, would miss early detection and BCG unresponsiveness in NMIBC (non-muscle invasive bladder cancer).

The BLADDR 2018 Congress took place in Madrid September 20-21. It is the 3rd Global Congress on Bladder Cancer and a major educational multidisciplinary event purely focusing on bladder cancer attended by specialists from all over the world.

Oslo, Norway, 20 September 2018: Photocure ASA (OSE: PHO), announces today that Daniel Schneider has been appointed President and Chief Executive Officer of Photocure. Mr Schneider joins Photocure from the position of General Manager for Ablynx N.V. in North America.

Blue light cystoscopy with Cysview was featured in Renal&Urology News by Dr.Gupta and Dr. Bivalacqua from the James Buchanan Brady Urologic Institute, Johns Hopkins Hospital in Baltimore. The authors highlight the essence of performing accurate cystoscopy and transurethral resection of bladder tumor (TURBT) for proper diagnosis, staging and surveillance of tumors in bladder cancer patients. Use of enhanced cystoscopy shows increased detection both in the operating room at the time of TURBT and in the outpatient surveillance setting.

Read more: https://bit.ly/2Om6uaB 

Oslo, Norway, August 27, 2018: Photocure ASA, The Bladder Cancer Company, announces today that an exclusive distribution agreement for the Nordic area for an innovative and patented medical device has been signed with Combat Medical (www.combat-medical.com). The device is designed for the delivery of Hyperthermic Intra-Vesical Chemotherapy (HIVEC^®) for non-muscle invasive bladder cancer and has a strong strategic and synergistic fit with current business.

Blue Light Cystoscopy with Cysview for surveillance cystoscopy featured in Health News Digest today:

Blue-light Technology improves identification of Bladder Cancer. Read the story and watch the video from UT Southwestern Medical Center in Dallas, TX, U.S.A here.

Oslo, Norway, 8 August 2018: Photocure ASA (OSE:PHO), today reported a revenue growth of 56% in local currency for the U.S. market in the second quarter of 2018, contributing to Hexvix/Cysview revenues of NOK 42.4 million (Q2 2017: NOK 37.6) and a recurring EBITDA of NOK 0.7 million (NOK -4.4 million). The company reiterates the positive outlook for the U.S. market with the reimbursement of Blue Light Cystoscopy (BLC(TM)) with Cysview, FDA approval of label expansion for Cysview and the launch of Cysview in combination with flexible cystoscopes in the surveillance of bladder cancer patients.

Photocure will present its second quarter and first half year report on Wednesday 8 August 2018 at Hotel Continental, Oslo, Norway.

Oslo, Norway, July 16, 2018: Photocure ASA (PHO:OSE) announced that the Patient Reported Outcomes (PRO) with Blue Light Cystoscopy (BLC™) with Cysview^® Study was published online, in the prestigious British Journal of Urology, International.

Oslo, Norway, 26 June 2018: Photocure ASA (OSE: PHO), announces today that President and Chief Executive Officer, Kjetil Hestdal, will step down effective 1 July 2018 as the company is entering a new growth phase with focus on global commercial development. The Board of Directors has initiated a search for his replacement and Chief Financial
Officer Erik Dahl is appointed as interim CEO. Mr. Hestdal will be available to the company until 30 December 2018.

Oslo, Norway, May 31, 2018: Photocure ASA (PHO:OSE) announced today that results from the Blue Light Cystoscopy (BLC™) with Cysview^® Registry Study was published on-line, in the prestigious official journal of the Society of Urological Oncology. Data from the publication showed that BLC significantly increases detection rates of flat, aggressive Carcinoma in Situ lesions (CIS) and papillary lesions compared to WLC alone and can result in upstaging or upgrading in about 14% of patients and that repeat use is safe.

Oslo, Norway, 23 May 2018: Photocure ASA (OSE:PHO), today reported a revenue growth of 36% in local currency for the important U.S. market in the first quarter of 2018, contributing to Hexvix/Cysview revenues of NOK 40.7 million (Q1 2017: NOK 36.5) and a recurring EBITDA of NOK -4.3 million (NOK -4.0 million). With the reimbursement of Blue Light Cystoscopy with Cysview, FDA approval of label expansion for Cysview and the launch of Cysview in combination with flexible cystoscopes in the surveillance of bladder cancer patients, the company expects a continued solid growth towards the 2020 ambitions.

Photocure will present its first quarter 2018 report on Wednesday 23 May 2018 at Hotel Continental, Oslo, Norway.